Topic:

R&D

Latest Headlines

Latest Headlines

Mapp's Ebola treatment comes through in a preclincal study

Tiny Mapp Biopharmaceutical's much-scrutinized Ebola treatment proved 100% effective in animal studies, the company said, stoking hopes that the investigational therapy can help curb an outbreak of the virus.

Servier and Amgen's cardio drug faces uncertain future after trial flop

Ivabradine, a heart rate-reducing drug from Servier and Amgen, failed to beat placebo in a huge study of patients with coronary artery disease, potentially clouding its future on two continents.

Dime-sized device can separate healthy and cancerous cells

MIT scientists have developed a dime-sized microfluidic device that can sort rare cancer cells from healthy ones using sound waves--an innovation that could have applications for cancer diagnosis, drug discovery and clinical research.

UPDATED: Setback forces Novo Nordisk to abandon anti-inflammatory R&D work, affecting 400 staffers

Among all the pharma companies, Novo Nordisk always stood out for its relentless R&D focus on diabetes and obesity. Today, the Danish company amped up that concentration another notch, jettisoning a group of clinical programs and winding down its work in anti-inflammatory treatments. And the pharma player added that the move would hit some 400 staffers, with close to half likely to lose their jobs at Novo.

Cenix lands an early-phase deal with BASF's Metanomics

German CRO Cenix BioScience has signed a deal with a BASF subsidiary to help ferret out new biomarkers, focusing on the growing field of metabolomics.

CRO Onyx signs up to help CRUK handle cancer R&D

Cancer Research UK has enlisted contract drugmaker Onyx Scientific to pitch in on some of its early research projects, handling development and manufacturing for clinical trials.

Boehringer to stay focused on porcine type 2 vaccine; dropping its RTU program

Boehringer Ingelheim said it will end research into developing a porcine circovirus type 2 ready-to-use vaccine combination to focus its attention on its PCV2 Mycoplasma hyopneumoniae vaccine.

Berg backs AI-driven discovery platform to save time, money in R&D

With its big claims about how artificial intelligence can slash drug development timelines and a lead candidate based on a coenzyme best known as a dietary supplement, Berg is always likely to provoke skepticism. But the company is sticking to its guns, with President and CTO Niven Narain pointing to early drug discovery successes as evidence of its legitimacy.

UPDATED: Cabozantinib flops against prostate cancer, forcing big job cuts at Exelixis

Late on Monday evening Exelixis put out the word that its crucial late-stage study of cabozantinib flunked a comparison study with prednisone for castration-resistant prostate cancer, triggering a restructuring that will eliminate 70% of the jobs at the biotech.

Amazon's meeting with FDA starts the rumor mill turning

Amazon is the latest tech giant to consider expanding into healthcare, but details of the online retailer's plans are sketchy.